CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing | Journal of Neuroscience
Frontiers | Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
Keep your enemies closer: targeting membrane-proximal domains for improved immunotherapy
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System: Molecular Therapy
The proposed interplay between CD33 and TREM2 in microglial... | Download Scientific Diagram
Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis - ScienceDirect
Evaluation of CD33 as a genetic risk factor for Alzheimer's disease | SpringerLink
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma: Molecular Therapy
The past and future of CD33 as therapeutic target in acute myeloid leukemia - ScienceDirect
Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach - Biomaterials Science (RSC Publishing) DOI:10.1039/C8BM01393D
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation | Haematologica
Frontiers | CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity
Cancers | Free Full-Text | Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
Cancers | Free Full-Text | Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
Cancers | Free Full-Text | CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
JCI - SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection
Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia | Scientific Reports
JCI - SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia - ScienceDirect
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia | Molecular Neurodegeneration | Full Text
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies | PNAS
CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape - ScienceDirect
Schematic diagram of the proposed pathway of CD33 siglec-mediated... | Download Scientific Diagram
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia | Leukemia
Deletion of Alzheimer's disease‐associated CD33 results in an inflammatory human microglia phenotype - Wißfeld - 2021 - Glia - Wiley Online Library
